You are here:Home/Market launch and sales situation
When INJEX Pharma first launched it´s products in 2012, they had a successful start. Within just months, the first 30,000 systems were sold, mainly in the US, Russia and Europe as well as in Asia, Australia and the MENA-region.
However due to mismanagement, an excessive internal cost problem, unreliable suppliers and subsequently quality issues, the company faced severe problems in late 2012. While demand was still there, the company was not able to deliver the appropriate quality and lost sales.
In 2013, the supervisory board fired management and installed Dr. Thomas Klaue as INJEX new CEO. In a rigid restructuring process the company slashed it´s fixed cost base by 80%, mainly by outsourcing production and subsequently cutting the labour force to essential activities such as development, quality management and regulatory affairs.
A quality management system based on scientific calculation methods was implemented to ensure quality. Distributors not performing were terminated. Scientific studies were prepared to bring INJEX closer to it´s goal to provide therapeutic solutions rather than just devices.